Cell Therapy
Shoreline Biosciences Reduces Staff Amid Uncertainty in Partnership with Gilead’s Kite
Shoreline Biosciences, Gilead Sciences, Kite Pharma, layoffs, cell therapy, strategic partnership
Astellas Terminates Development of Autologous Cell Therapy for Lymphoma Following Pipeline Review
Astellas, lymphoma, CAR-T cell therapy, autologous cell therapy, pipeline review, cancer treatment, biotechnology
Mesoblast Secures FDA Approval for Ryoncil, First Mesenchymal Stromal Cell Therapy for Pediatric Steroid-Refractory Acute Graft-Versus-Host Disease
Mesoblast, Ryoncil, FDA Approval, Mesenchymal Stromal Cell Therapy, Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD), Pediatric Patients, Cell Therapy
Bristol Myers Squibb Terminates Cell Therapy Collaborations with Immatics and Century Therapeutics
Bristol Myers Squibb, Immatics, Century Therapeutics, cell therapy, portfolio review, collaboration termination
Bristol Myers Squibb Terminates Cell Therapy Collaborations with Immatics and Century Therapeutics Amid Cost-Cutting Measures
Bristol Myers Squibb, Immatics, Century Therapeutics, cell therapy, cost-cutting, strategic productivity initiative, portfolio prioritization
Editas Medicine Undergoes Major Restructuring, Cutting 65% of Staff and Halting Sickle Cell Therapy Development
Editas Medicine, layoffs, restructuring, sickle cell therapy, CRISPR gene editing, biotech industry
Breakthroughs in Bladder Cancer Treatment: Protara and CG Oncology Report Encouraging Outcomes
Bladder Cancer Treatment, Protara Therapeutics, CG Oncology, TARA-002, Cretostimogene Grenadenorepvec, Non-Muscle Invasive Bladder Cancer (NMIBC), Oncolytic Immunotherapy, Cell Therapy
Protara’s TARA-002 Cell Therapy Shows Exceptional Promise in Treating Non-Muscle Invasive Bladder Cancer
Protara Therapeutics, TARA-002, Non-Muscle Invasive Bladder Cancer (NMIBC), Phase 2 ADVANCED-2 trial, Cell therapy, BCG-Unresponsive, BCG-Naïve
Roche Acquires Poseida Therapeutics for Up to $1.5 Billion, Expanding Off-the-Shelf CAR-T Capabilities
Roche, Poseida Therapeutics, CAR-T therapy, off-the-shelf cell therapies, allogeneic cell therapy, biotech acquisition
Roche Acquires CAR-T Partner Poseida Therapeutics for $1 Billion Upfront
Roche, Poseida Therapeutics, CAR-T, cell therapy, acquisition, biotechnology, pharmaceuticals